-The Times of India Overuse of antibiotics has led to a situation in which even simple infections acquired outside the hospital are turning drug-resistant. This has been revealed in a recent study conducted by a city private hospital on ICU patients. It showed that nearly one-fourth of all admissions due to infection of the urinary tract, pneumonia or blood stream infection were community-acquired which means that these people contracted the drug-resistant...
More »SEARCH RESULT
Bacteria are becoming bolder-Dr. Bala Ramachandran
-The Hindu Antibiotics are often used as an excuse for poor infection control Arjun (name changed) is an 8-year-old boy who was being treated for breathing difficulty in a hospital in one of the southern cities. He had suffered on and off with cough/cold since infancy and had been treated multiple times with antibiotics. His parents were not highly educated and hoped that he would get better as he grew older. This...
More »The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri
-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »